
The EBMH Notebook summarises key messages about generalised anxiety disorder, sourced from: Clin Evid Concise2004 (in press); www.clinicalevidence.com. For this review, Clinical Evidence Concise searched and appraised material published until June 2003. Generalised anxiety disorder (GAD) is defined as excessive worry and tension about every day events and problems on most days, for at least six months, to the point where the person experiences distress or has marked difficulty in performing day to day tasks.1 It may be characterised by the following symptoms and signs: increased motor tension (fatigability, trembling, restlessness, and muscle tension); autonomic hyperactivity (shortness of breath, rapid heart rate, dry mouth, cold hands, and dizziness); and increased vigilance and scanning (feeling keyed up, increased startling, and impaired concentration), but not panic attacks.1 One non-systematic review of epidemiological and clinical studies found marked reduction of quality of life and psychosocial functioning in people with anxiety disorders (including GAD).2 It also found that people with GAD have low overall life satisfaction and some impairment in ability to fulfil roles, social tasks, or both.2 One overview of observational studies published in English found that the prevalence of GAD among adults in the community is 1.5–3.0%.3 It found that 3–5% of adults have had GAD in the past year and 4–7% have had GAD during their life. The US National Comorbidity Survey found that over 90% of people diagnosed with GAD had a comorbid diagnosis, including dysthymia (22%), depression (39–69%), somatisation, other anxiety disorders, bipolar disorder, or substance abuse.4 The Harvard Brown Anxiety Research Program also found that only 30/180 (17%) people had GAD …
Psychiatric Status Rating Scales, Cognitive Behavioral Therapy, Relaxation Therapy, Anxiety Disorders, Combined Modality Therapy, Buspirone, Antidepressive Agents, Benzodiazepines, Treatment Outcome, Meta-Analysis as Topic, Anti-Anxiety Agents, Risk Factors, Hydroxyzine, Humans, Antipsychotic Agents, Follow-Up Studies, Randomized Controlled Trials as Topic, Kava, Phytotherapy, Carbolines
Psychiatric Status Rating Scales, Cognitive Behavioral Therapy, Relaxation Therapy, Anxiety Disorders, Combined Modality Therapy, Buspirone, Antidepressive Agents, Benzodiazepines, Treatment Outcome, Meta-Analysis as Topic, Anti-Anxiety Agents, Risk Factors, Hydroxyzine, Humans, Antipsychotic Agents, Follow-Up Studies, Randomized Controlled Trials as Topic, Kava, Phytotherapy, Carbolines
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 8 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
